{
    "clinical_study": {
        "@rank": "36667", 
        "acronym": "HCV/Hemophilia", 
        "arm_group": [
            {
                "arm_group_label": "Lead -In", 
                "arm_group_type": "Active Comparator", 
                "description": "Response Guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon  + Ribavirin + Telaprevir followed by 8 weeks of PegInterferon + Ribavirin."
            }, 
            {
                "arm_group_label": "No Lead -in", 
                "arm_group_type": "Active Comparator", 
                "description": "Response Guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by 12 weeks of PegInterferon + Ribavirin"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine treatment response in subjects with chronic hepatitis C and\n      hemophilia with pegylated interferon + ribavirin and telaprevir."
        }, 
        "brief_title": "Viral Kinetics in HCV Clearance in Subjects With Hemophilia", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C With Hemophilia", 
        "condition_browse": {
            "mesh_term": [
                "Hemophilia A", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "Previous clinical trials for treatment of chronic hepatitis C have excluded subjects with\n      hemophilia from participating."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Hemophilia A or B\n\n          2. HCV RNA positive (PCR or branched-chain DNA Methods), Genotype 1 (a/b, mixed and\n             unknown subtype)\n\n          3. Chronic HCV infection evidenced by HCV serology, HCV RNA or liver enzyme\n             abnormalities present at least 6 months prior to enrollment\n\n          4. Liver biopsy or non-invasive marker that permits fibrosis staging within 12 months of\n             enrollment. If a biopsy was not performed within 1 year, non-invasive markers may be\n             utilized during screening period. Cirrhosis is not an exclusion factor\n\n          5. Age \u2265 18 years\n\n          6. Prior HCV treatment na\u00efve or experienced\n\n          7. HCV viral load detectable during screening period\n\n          8. Absence of exclusion criteria\n\n          9. Sexually active subjects (both male and female) must agree and commit to the use of a\n             medically acceptable form of contraception for the duration of the study and for 6\n             months following the last dose of study medication. Medically acceptable forms of\n             contraception include oral contraceptives, injectable or implantable methods,\n             intrauterine devices or properly used barrier contraception.\n\n        Exclusion Criteria:\n\n          1. Hemoglobin <11\n\n          2. Pregnancy (during screening period or any time during treatment)\n\n               1. females, that are planning to become pregnant or are breastfeeding\n\n               2. males, whose partner is pregnant or is planning to become pregnant\n\n          3. HIV Infection\n\n          4. Prior History of:\n\n               1. Hepatitis B (HBsAG negative - must have documentation of negative results within\n                  one year prior to enrollment or during screening period if not performed in that\n                  time window\n\n               2. Homozygotic alpha-1-anti-trypsin (a1AT) deficiency - documentation of a1AT level\n                  <80 (at anytime prior to  screening). If <80, phenotype testing should not\n                  demonstrate zz phenotype. All other phenotypes are not exclusionary,\n\n               3. History of Homozygotic Genetic Hemochromatosis (at anytime prior to enrollment)\n                  with evidence of iron overload requiring phlebotomy,\n\n               4. Autoimmune markers (antinuclear antibody (ANA) and/or antismooth muscle antibody\n                  (ASMA)) >1:160.\n\n               5. Any other significant liver disease or process (to be determined by the\n                  investigator). Non-alcoholic fatty-liver disease (NAFLD) is not an exclusion.\n\n          5. History of Decompensated liver disease evidenced by any prior history of hepatic\n             encephalopathy (Grade 2 or higher), ascites, variceal bleeding; Platelet count <\n             100,000\n\n          6. Active thyroid disease (OK if on thyroid replacement with normal thyroid-stimulating\n             hormone (TSH); if TSH abnormal must have normal free thyroid index)\n\n          7. Chronic renal insufficiency, defined as creatinine clearance < 50 ml/min. (estimated\n             by Modification of Diet in Renal Disease (MDRD) formula)\n\n          8. Life-threatening disease processes that could preclude completion of trial in opinion\n             of investigator.\n\n          9. Any condition which the investigator feels will preclude safe completion of the\n             treatment regimen including severe psychiatric disorders, active alcohol or\n             recreational drug abuse.\n\n         10. Inability to provide informed consent.\n\n         11. Use of systemic corticosteroids or immunomodulatory drugs within 1 month (Nasal\n             steroids are permitted.)\n\n         12. Uncontrolled seizure disorder (in opinion of investigator)\n\n         13. Concurrent autoimmune processes with active disease that may be exacerbated by\n             interferon-based therapies (e.g. Crohn's Disease, Rheumatoid arthritis) in the\n             opinion of the investigator. Psoriasis permitted if controlled with topical\n             medications at the time of study enrollment.\n\n         14. Use of prohibited medications (as described in the telaprevir package insert) within\n             14  days of the first dose of study medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704521", 
            "org_study_id": "12053004", 
            "secondary_id": "R34HL109334"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lead -In", 
                    "No Lead -in"
                ], 
                "intervention_name": "Lead -In- PegInterferon + Ribavirin (4 weeks); PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon + Ribavirin (8 weeks)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Lead -In", 
                    "No Lead -in"
                ], 
                "intervention_name": "No Lead-in - No 4-week lead in therapy; PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon+ Ribavirin (12 weeks)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis C", 
            "HCV", 
            "Hemophilia"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45267"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Viral Kinetic Models of HCV Clearance in Hemophiliacs With Telaprevir", 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Kenneth E Sherman, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will be randomized to either \"lead-in\" 4 weeks with Peginterferon + Ribavirin or no lead-in, followed by response guided therapy of 24 or 48 weeks based on viral response to treatment. Standard of care treatment stopping rules will be followed with assessment of viral response at week 12 of treatment.", 
            "measure": "Viral Kinetic Models of HCV Clearance in Hemophiliacs with Telaprevir", 
            "safety_issue": "Yes", 
            "time_frame": "Viral kinetics at Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704521"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Kenneth Sherman", 
            "investigator_title": "Kenneth E. Sherman, MD, PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of Cincinnati", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Vertex Pharmaceuticals Incorporated", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Genentech", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Kenneth Sherman", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}